2-甲乙醇和过氧化作为帕金森病有前途的生物标志物
Paulina Bastian1, Lucyna Konieczna2, Jarosław Dulski3,4,5
1Department of Medical Chemistry, Medical University of Gdansk, 80-210, Gdansk, Poland. paulina.bastian@gumed.edu.pl.
Molecular neurobiology
|August 17, 2023
概括
2-甲索二醇 (2-ME2) 可能预防癌症,但会导致神经退行,诱导神经元中的氧化应激和亡. 帕金森病 (PD) 患者中甲基雌激素和过氧化的升高表明潜在的PD生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 生物化学 生物化学
背景情况:
- 雌激素会影响大脑细胞的发育.
- 2-甲索二醇 (2-ME2),一种雌激素代谢物,通过影响分裂细胞,表现出抗癌性质.
- 2-ME2在癌症预防和神经退行症中的双重作用需要研究.
研究的目的:
- 为了评估2-ME2在帕金森病 (PD) 中的神经保护或神经退行潜力,实验室模型.
- 为了研究2-ME2在PD患者的神经毒性作用的临床相关性.
- 为了确定神经退行性疾病的潜在生物标志物.
主要方法:
- 使用SH-SY5Y神经母细胞瘤细胞在体外模型中利用帕金森病 (PD).
- 评估了2-ME2对氧化应激,热冲击蛋白 (HSP),DNA损伤和亡的影响.
- 采用LC-MS/MS测量雌激素衍生物和停止流量方法测量患者血液中过氧化 (H2O2) 水平.
主要成果:
- 在PD模型中,2-ME2诱导了氧化应激,控制了HSP,导致DNA链断裂和亡.
- 与对照组相比,在PD患者中观察到甲氧雌激素和H2O2的水平增加.
- 在PD患者中,氧雌激素水平降低,而甲氧雌激素和H2O2水平升高.
结论:
- 2-ME2具有双重作用:潜在的抗癌活性和神经退行性风险.
- 血中甲基雌激素和H2O2的升高可能作为帕金森病 (PD) 的新生物标志物.
- 需要进一步的研究,以了解这些发现对神经退行性疾病的临床影响.
相关概念视频
Parkinson's Disease: Treatment
297
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
297
Parkinson's Disease: Overview
596
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
596


